Gifu Kyoritsu University

Recent papers from Gifu Kyoritsu University

1. WFUMB-Recommended Versus Manufacturer-Optimized Protocols for Ultrasound-Guided Attenuation Parameter in Hepatic Steatosis Assessment: A Retrospective Single-Vendor Multicenter StudyJournal of Clinical Medicine · 2026
2. Rapid genome-wide purging following tsunami-induced hybridization in a stickleback populationNature Ecology & Evolution · 2026
3. Sex Differences in Sentiment-Scored Vocabulary Patterns in VAERS Free-Text Narratives of Four Major Vaccine CategoriesBiological and Pharmaceutical Bulletin · 2026
4. Response to the Letter Regarding “Methodological Considerations in Real‐World Evaluation of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma”Journal of Gastroenterology and Hepatology · 2026
5. Response to the Letter Regarding “Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial”Journal of Gastroenterology and Hepatology · 2026
6. Baseline DCP May Modify Response to Atezolizumab‐Bevacizumab Versus Durvalumab‐Tremelimumab in Unresectable HCCLiver International · 2026
7. Establishment of prohaptoglobin-specific antibody and haptoglobin detection systems as biomarkers for pancreatic diseasesThe Journal of Biochemistry · 2026
8. No evidence for temperature-dependent selection on lateral plate variation in the three-spined stickleback: a single-replicate mesocosm experimentCanadian Journal of Zoology · 2026
9. Simplified BALAD (BALAD‐S) Score as a Guide for First‐Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular CarcinomaHepatology Research · 2026
10. IgA-enriched phenotype predicts liver-related events in MASLDJournal of Hepatology · 2026
11. The Fibrosis-3 (FIB-3) Index: An Age-Independent Score for Liver Fibrosis — Development and Clinical ApplicationsKanzo · 2026
12. Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline—A Step Towards Functional Cure or a Marginal Margin? Authors' ReplyAlimentary Pharmacology & Therapeutics · 2026
13. Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA TrialJournal of Gastroenterology and Hepatology · 2026
14. Ablation‐Based Salvage Strategy at Disease Progression After Initial Disease Control With Atezolizumab/Bevacizumab in Hepatocellular CarcinomaHepatology Research · 2026
15. Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world studyHepatology · 2026
16. Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects ModelsAlimentary Pharmacology & Therapeutics · 2026
17. Diagnostic Impact of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Retrospective Study.2026
18. Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus BevacizumabHepatology Research · 2026
19. Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus BevacizumabHepatology Research · 2026
20. Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular CarcinomaLiver international communications. · 2026